Evidence map›Paper›PMID 35144008›Full record

ArticleOphthalmology. Glaucoma

Clinicians' Use of Quantitative Information When Assessing the Rate of Structural Progression in Glaucoma.

Stuart K Gardiner, Robert M Kinast, Teresa C Chen, Nicholas G Strouthidis, Carlos Gustavo De Moraes, Kouros Nouri-Mahdavi, Jonathan S Myers, Jin Wook Jeoung, John T Lind, Lindsay A Rhodes and 2 more

Open access · greenAbstract read
In one paragraph

Article in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 4 countries.

Stuart K GardinerDevers Eye Institute, Legacy Health, Portland, Oregon. Electronic address: sgardiner@deverseye.org.
Robert M KinastDevers Eye Institute, Legacy Health, Portland, Oregon.
Teresa C ChenHarvard Medical School, Massachusetts Eye & Ear, Boston, Massachusetts.
Nicholas G StrouthidisNIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom; Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, NSW, Australia.
Carlos Gustavo De MoraesColumbia University Irving Medical Center, New York, New York.
Kouros Nouri-MahdaviStein Eye Institute, University of California Los Angeles, Los Angeles, California.
Jonathan S MyersWills Eye Hospital, Philadelphia, Pennsylvania.
Jin Wook JeoungSeoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
John T LindGlick Eye Institute, Indiana University School of Medicine, Indianapolis, Indiana.
Lindsay A RhodesUniversity of Alabama at Birmingham, Birmingham, Alabama.
Donald L BudenzDepartment of Ophthalmology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
Steven L MansbergerDevers Eye Institute, Legacy Health, Portland, Oregon.
Legacy Health · USColumbia University Irving Medical Center · USMassachusetts Eye and Ear Infirmary · USMidwest Eye Institute · USSeoul National University Hospital · KRThe University of Sydney · AUUniversity of Alabama at Birmingham · USUniversity of California, Los Angeles · USUniversity of North Carolina at Chapel Hill · USWills Eye Hospital · US

Funding

Visual Phenotyping CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul Douglas Gamlin · 1985 to 2026
$16.9M
Functional Testing for GlaucomaR01EY020922 · NEI · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI GARDINER, STUART · 2011 to 2021
$3.2M
Blood flow and hemodynamics in glaucomaR01EY031686 · NEI · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI GARDINER, STUART · 2020 to 2023
$1.8M
NEI NIH HHS P30 EY003039NEI NIH HHS R01 EY020922NEI NIH HHS R01 EY031686
6 · The paper itself

Abstract

purposeOCT scans contain large amounts of information, but clinicians often rely on reported layer thicknesses when assessing the rate of glaucomatous progression. We sought to determine which of these quantifications most closely relate to the subjective assessment of glaucoma experts who had all the diagnostic information available.

designProspective cohort study.

participantsEleven glaucoma specialists independently scored the rate of structural progression from a series of 5 biannual clinical OCT printouts.

methodsA total of 100 glaucoma or glaucoma suspect eyes of 51 participants were included; 20 were scored twice to assess repeatability. Scores ranged from 1 (improvement) to 7 (very rapid progression). Generalized estimating equation linear models were used to predict the mean clinician score from the rates of change of retinal nerve fiber layer thickness (RNFLT) or minimum rim width (MRW) globally or in the most rapidly thinning of the 6 sectors.

main outcome measuresThe correlation between the objective rates of change and the average of the 11 clinicians' scores.

resultsAverage RNFLT within the series of study eyes was 79.3 μm (range, 41.4-126.6). Some 95% of individual clinician scores varied by ≤ 1 point when repeated. The mean clinician score was more strongly correlated with the rate of change of RNFLT in the most rapidly changing sector in %/year (pseudo-R

conclusionsThe rate of change of RNFLT in the most rapidly changing sector predicted experts' assessment of the rate of structural progression better than global rates or MRW. Sectoral rates may be a useful addition to current clinical printouts.

Indexed as

GlaucomaOptic DiskHumansIntraocular PressureNerve FibersProspective StudiesRetinal Ganglion CellsTomography, Optical CoherenceClinical careDiagnostic testingOCTSurvey

Identifiers

PMID35144008
PMCPMC9357231
OpenAlexW4210839340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.